Navigation Links
Ceregene Announces Two Key Additions to Leadership Team
Date:4/23/2008

SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its management team. Maurice Mezzino has been hired to the position of vice president, chief business officer, and Andrea Loewen-Rodriguez joins the company as senior director, regulatory affairs. These positions have been created to support development and commercial activities as Ceregene transitions to a later stage biotechnology company with two product candidates in clinical trials -- CERE-110 for Alzheimer's disease and CERE-120 for Parkinson's disease.

"We are excited to add two such experienced professionals to our leadership team during a time when we are advancing our product candidates into late-stage clinical development, with CERE-120 for Parkinson's disease potentially entering Phase 3 clinical trials next year," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer. "Maurice will be a key contributor toward our business and partnering strategies having structured and completed multiple deals during his career, and Andrea will play an important role in liaising with the FDA and European regulators in our efforts to move our therapies through the approval process."

Maurice Mezzino, a business development executive with more than 20 years of biopharmaceutical industry experience, joins us from Biogen Idec, where he has been since 2000, serving most recently as vice president, business development, responsible for managing the west coast business development team. Among his accomplishments, Mr. Mezzino spearheaded an oncology strategic alliance between IDEC and Biogen in 2003, which was a precursor to the merger between the companies later that year; and in 2006 he led the acquisition of Conforma Therapeutics. Prior to Biogen Idec, Mr. Mezzino held a variety of positions in clinical development, business planning, strategic marketing and business development at Bristol-Myers Squibb Company, Schering-Plough Corporation, Hoechst-Roussel Pharmaceuticals and Ayerst Laboratories. Maurice received a BA degree in environmental biology from Rutgers University, an MS degree in microbiology from Louisiana State University and an MBA in finance from Fairleigh Dickinson University. He is also a Chartered Financial Analyst (CFA).

Andrea Loewen-Rodriguez, a regulatory affairs professional with more than 18 years of biopharmaceutical industry experience, joins us from the regulatory affairs division at Biogen Idec, where she has been since 2000. Her responsibilities included developing and implementing global regulatory strategies and submissions for multiple products in clinical development. Prior to Biogen Idec, Ms. Loewen-Rodriguez held various positions with Nexell Therapeutics and Baxter Healthcare Corp. Andrea holds a Regulatory Affairs Certification and received her BA degree in biology from Gustavus Adolphus College.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE) as well as Hamilton BioVentures and California Technology Partners.


'/>"/>
SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
3. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
4. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
5. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
6. BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
7. UltraTape Announces Sample Kits Available for Purchase Through Website
8. IMPAC Medical Systems Announces 2008 Laboratory Professionals of the Year
9. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
10. Fufeng Announces 2007 Annual Results
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... , ... August 11, 2017 , ... Algenist continues to ... formulation unlocking collagen like never before. , Collagen is the key structural element ... market with Liquid Collagen™, which include: , First to ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia ... August 14th through the 16th, the University City Science Center will kick off ... 2016, provides Philadelphia-based middle school educators an opportunity for professional development related to ...
(Date:8/10/2017)... Bahama (PRWEB) , ... August 09, 2017 , ... Okyanos ... will take place at the Pelican Bay Hotel in Freeport, Grand Bahama on September ... pre-registration is required. , With oversight from the Ministry of Health’s National Stem ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... establishing Kinokuniya Company Ltd. as its exclusive sales representative for SPIE Journals in ... for the SPIE Digital Library in Japan. , “We look forward to expanding ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):